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Introduction {#aos14472-sec-0005}
============

The ongoing outbreak of the novel coronavirus disease (COVID‐19) has been declared by WHO as a global public health emergency. COVID‐19 was first reported in Wuhan, China, in December 2019, followed by an outbreak across Hubei Province, other parts of China and now all over the world, particularly in America, Spain, Italy and Germany (Huang et al. [2020](#aos14472-bib-0006){ref-type="ref"}). This serious infectious disease is caused by a novel enveloped RNA betacoronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) (Lu et al. [2020](#aos14472-bib-0007){ref-type="ref"}, [2020](#aos14472-bib-0008){ref-type="ref"}a,b). A study in the *New England Journal of Medicine* by Zhong Nanshan and colleagues reported nine cases with conjunctival congestion among the 1,099 cases enrolled (Guan et al., [2020](#aos14472-bib-0005){ref-type="ref"}). Besides, a recent paper found that 31.6% COVID‐19 patients had ocular manifestations consistent with conjunctivitis, including conjunctival hyperaemia, chemosis, epiphora or increased secretions (Wu et al. [2020](#aos14472-bib-0015){ref-type="ref"}). However, the complete profiling of COVID‐19‐related ocular symptoms, eye protections and other ocular characteristics is still insufficient. Several infected cases presented firstly with conjunctivitis before the onset of pneumonia, implying that the ocular route might be the potential transmission route of SARS‐CoV‐2 virus under certain conditions (Lu et al. [2020](#aos14472-bib-0007){ref-type="ref"}, [2020](#aos14472-bib-0008){ref-type="ref"}a,b; Xia et al., [2020](#aos14472-bib-0016){ref-type="ref"}). A recent study revealed that SARS‐CoV‐2 also uses the cell entry receptor, angiotensin‐converting enzyme 2 (ACE2), similar to SARS‐CoV (Wan et al., [2020](#aos14472-bib-0014){ref-type="ref"}; Zhou et al., [2020](#aos14472-bib-0018){ref-type="ref"}). Moreover, the expression and activity of ACE2 can be detected in the ocular surface, including the cornea and conjunctiva, which provides transocular entry potential for SARS‐CoV‐2 (Sun et al., [2004](#aos14472-bib-0012){ref-type="ref"}).

Several urgent questions need to be addressed, including (1) What are the detailed profiles of COVID‐19‐related ocular symptoms and diseases? (2) What are the clinical characteristics of COVID‐19 patients with conjunctival congestion? and (3) Can COVID‐19 spread through the ocular route or present as the primary infected site? To answer these questions, it is essential to perform ocular screening among patients with COVID‐19. To our knowledge, comprehensive ophthalmological data on COVID‐19 are still missing.

Hence, the present cross‐sectional study was designed to describe the ophthalmic characteristics of COVID‐19 patients in Wuhan, aiming to get a complete ocular screening of COVID‐19, which may provide clinical clues for the diagnosis and treatment of the disease and a theoretical basis for appropriate protection guidelines in the population.

Materials and Methods {#aos14472-sec-0006}
=====================

Study population {#aos14472-sec-0007}
----------------

The study was conducted in accordance with the Declaration of Helsinki. It has been approved by the ethics committee of Tongji Hospital and the China Ethics Committee for Registering Clinical Trials (ChiCTR2000030489). Informed consent was obtained from the patients involved.

A total of 3149 patients were recruited from 1 February to 1 March 2020, at Mobile Cabin Hospital of Optical Valley and Tongji Hospital of Huazhong University of Science and Technology in Wuhan, China. The exclusion criteria were as follows: (1) current hospitalized patients; (2) severe COVID‐19 patients; (3) patients without smartphone; (4) unable to contact by telephone; and (5) refused questionnaire. After evaluation with the exclusion criteria, a total of 535 patients were finally valid for the study (flow chart presented in Fig. [1](#aos14472-fig-0001){ref-type="fig"}). Diagnosis and classifications of COVID‐19 were made according to the novel coronavirus infection pneumonia diagnosis and treatment guideline, 7th edition ([National Health Commission of the people\'s republic of China](#aos14472-bib-0009){ref-type="ref"}).

![Flow chart for the study profile. A total of 535 patients were finally valid for the study.](AOS-9999-na-g001){#aos14472-fig-0001}

Data collection {#aos14472-sec-0008}
---------------

Demographic, epidemiological, clinical, laboratory and radiologic data were obtained from patients' electronic medical records and an electronic questionnaire completed by patients on a smartphone. Data about ocular manifestation, the use of eye drops and eye protection were obtained by ophthalmologists via telephone. If data were missing from the questionnaire or clarification was needed, we communicated directly with the patient by telephone after obtaining informed consent. Two researchers independently reviewed the data collection forms to double‐check the data collected.

For the reason of safety and disease control, the slit lamp examinations or other ophthalmic examinations cannot be realized. For the patients reporting conjunctival congestion or conjunctivitis, we further did the basic ophthalmologic examinations with flashlight or send them a representative picture of conjunctival congestion to confirm their symptoms.

Nucleic acid detection of SARS‐CoV‐2 in nasopharyngeal swabs {#aos14472-sec-0009}
------------------------------------------------------------

Nasopharyngeal swabs were collected from all patients by a trained healthcare worker using protective equipment. The swab samples were maintained in a viral‐transport medium stored between 2°C and 8°C.

All samples were analysed by conventional qualitative reverse transcription polymerase chain reaction (RT‐PCR). RNA was extracted from the clinical samples using a viral RNA kit. A 25 μl reaction containing 5 μl of RNA, 12.5 μl of 2 × reaction buffer provided with the one‐step RT‐PCR system with Platinum Taq Polymerase (Invitrogen, Darmstadt, Germany; containing 0.4 mM of each deoxyribont triphosphates (dNTP) and 3.2 mM magnesium sulphate), 1 μl of reverse transcriptase/Taq mixture from the kit, 0.4 μl of a 50 mM magnesium sulphate solution (Invitrogen), and 1 μg of nonacetylated bovine serum albumin. The SARS‐CoV‐2 specific primers are as follows: forward primer 5′‐ACTTCTTTTT CTTGCTTTCGTGGT‐3′; reverse primer 5′‐GCAGCAGTACGCACACAATC‐3′; and the probe 5′CY5‐CTAGTTACACTAGCCATCCTTACTGC‐3′BHQ1. (Huang et al. [2020](#aos14472-bib-0006){ref-type="ref"}) These primers were used to detect the presence of SARS‐CoV‐2 RNA. All oligonucleotides were synthesized and provided by Tib‐Molbiol (Berlin, Germany). The RT‐PCR condition was developed by the Clinical Laboratory of Tongji Hospital. Thermal cycling was performed at 55°C for 10 min for reverse transcription, followed by 95°C for 3 min and then 45 cycles of 95°C for 15 s and 58°C for 30 s.

Statistical analysis {#aos14472-sec-0010}
--------------------

Continuous variables were expressed as medians (interquartile range, IQR) and compared with the Kruskal--Wallis test. Categorical variables were summarized as counts (percentages) and compared by chi‐square test or Fisher's exact test. Univariate and multivariate regression analysis were used to evaluate correlations between ocular protections and conjunctival congestion. No imputation was made for missing data. All the analyses were performed using Empower (R) ([www.empowerstats.com](http://www.empowerstats.com), X&Y Solutions, Inc. Boston, MA) and R ([http://www.R‐project.org](http://www.R-project.org)).

Results {#aos14472-sec-0011}
=======

Demographics and baseline characteristics of COVID‐19 patients by conjunctival congestion {#aos14472-sec-0012}
-----------------------------------------------------------------------------------------

A total of 535 COVID‐19 patients (27 with conjunctival congestion) were enrolled in the study. The demographic data, exposure history and past medical history are summarized in Table [1](#aos14472-tbl-0001){ref-type="table"}.

###### 

Demographics and baseline characteristics of COVID‐19 patients by conjunctival congestion.

  **Demographics and baseline characteristics**          **Without conjunctival congestion (N = 508)**   **With conjunctival congestion (N = 27)**   **p value**
  ------------------------------------------------------ ----------------------------------------------- ------------------------------------------- -----------------------------------------------
  Median age (IQR) -- years                              44.0 (34.0--54.2)                               44.0 (28.5--53.5)                           0.529
  Age group -- no. (%)                                                                                                                               
  \<15 year                                              0                                               0                                           0.211
  15--44 year                                            259 (51.0%)                                     15 (55.6%)                                   
  45--64 year                                            235 (46.3%)                                     10 (37.0%)                                   
  ≥65 year                                               14 (2.8%)                                       2 (7.4%)                                     
  Female sex -- no. (%)                                  255 (50.2%)                                     12 (44.4%)                                  0.56
  Occupation                                                                                                                                         0.008[\*](#aos14472-note-0004){ref-type="fn"}
  Employee                                               207 (45.8%)                                     5 (20.0%)                                    
  Self‐employed                                          85 (18.8%)                                      5 (20.0%)                                    
  Unemployed                                             79 (17.5%)                                      4 (16.0%)                                    
  Retired                                                36 (8.0%)                                       3 (12.0%)                                    
  Agricultural worker                                    22 (4.9%)                                       3 (12.0%)                                    
  Student                                                9 (2.0%)                                        3 (12.0%)                                    
  Medical staff                                          14 (3.1%)                                       2 (8.0%)                                     
  Smoking history -- no. (%)                                                                                                                         0.464
  Never smoked                                           456 (89.8%)                                     23 (85.2%)                                   
  Former smoker                                          29 (5.7%)                                       2 (7.4%)                                     
  Current smoker                                         23 (4.5%)                                       2 (7.4%)                                     
  Exposure history within past 14 days -- no. (%)                                                                                                     
  Huanan Seafood Wholesale Market                        5 (1.0%)                                        0                                           1.000
  Contact with person with fever                         149 (29.3%)                                     10 (37.0%)                                  0.393
  Contact with COVID‐19 patient in family or community   193 (38.0%)                                     10 (37.0%)                                  0.921
  Chronic medical illness -- no. (%)                                                                                                                  
  Hypertension                                           65 (12.8%)                                      5 (18.5%)                                   0.390
  Diabetes mellitus                                      37 (7.3%)                                       1 (3.7%)                                    0.712
  Hyperlipidaemia                                        6 (1.2%)                                        0                                           1.000
  Cardiovascular and cerebrovascular diseases            18 (3.5%)                                       0                                           1.000
  Respiratory system disease                             36 (7.1%)                                       1 (3.7%)                                    1.000
  Haematological system disease                          3 (0.6%)                                        0                                           1.000
  Chronic kidney disease                                 3 (0.6%)                                        0                                           1.000
  Chronic liver disease                                  25 (4.9%)                                       0                                           1.000
  Autoimmune disease                                     8 (1.6%)                                        2 (7.4%)                                    0.086

Data are presented as median (IQR) or number (percentage). p values are calculated from Kruskal--Wallis test, chi‐square test or Fisher's exact test.

p value \< 0.05.
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The median age of patients with or without conjunctival congestion was 44 years. The majority (55.6% and 51.0%, respectively) were aged 15--44 years. There was a similar proportion of men and women (15/12 and 253/255, respectively) in the two groups. Nearly half (45.8%) of the patients without conjunctival congestion employed, and 14 (3.1%) infected cases were medical staff; 3 (12.0%) patients with conjunctival congestion were agricultural workers, and 2 (8.0%) patients were medical staff. Among all the subjects with or without conjunctival congestion, most had a contact history with a person with a fever (37.0% and 29.3%, respectively) or with a confirmed COVID‐19 case in the family or community (37.0% and 38.0%, respectively). The top three ranked chronic illnesses were same in patients with or without conjunctival congestion, including hypertension (18.5% and 12.8%, respectively), diabetes mellitus (3.7% and 7.3%, respectively) and respiratory system disease (3.7% and 7.1%, respectively).

Clinical characteristics of COVID‐19 patients by conjunctival congestion {#aos14472-sec-0013}
------------------------------------------------------------------------

The clinical characteristics, including the common symptoms of COVID‐19, the radiologic findings of chest CT and the PCR results of SARS‐CoV‐2 detection, in nasopharyngeal swabs are summarized in Table [2](#aos14472-tbl-0002){ref-type="table"}.

###### 

Clinical characteristics of COVID‐19 patients by conjunctival congestion.

  **Clinical characteristics**                    **Without conjunctival congestion (N = 508)**   **With conjunctival congestion (N = 27)**   **p value**
  ----------------------------------------------- ----------------------------------------------- ------------------------------------------- -------------
  Symptoms -- no. (%)                                                                                                                          
  Fever                                           309 (60.8%)                                     18 (66.7%)                                  0.544
  Highest temperature                                                                                                                         0.582
  \<37.3°C                                        199 (39.2%)                                     9 (33.3%)                                    
  37.3--38°C                                      93 (18.3%)                                      7 (25.9%)                                    
  38.1--39.0°C                                    170 (33.5%)                                     10 (37.0%)                                   
  \>39.0°C                                        46 (9.1%)                                       1 (3.7%)                                     
  Cough                                           329 (64.8%)                                     20 (74.1%)                                  0.322
  Sore throat                                     103 (20.3%)                                     6 (22.2%)                                   0.807
  Fatigue                                         196 (38.6%)                                     14 (51.9%)                                  0.169
  Poor appetite                                   139 (27.4%)                                     7 (25.9%)                                   0.870
  Chest stuffiness                                169 (33.3%)                                     9 (33.3%)                                   0.994
  Shortness of breath                             84 (16.5%)                                      4 (14.8%)                                   1.000
  Dyspnoea                                        113 (22.2%)                                     7 (25.9%)                                   0.655
  Nasal discharge                                 22 (4.3%)                                       3 (11.1%)                                   0.125
  Nasal congestion                                24 (4.7%)                                       3 (11.1%)                                   0.149
  Headache                                        115 (22.6%)                                     6 (22.2%)                                   0.960
  Myalgia or arthralgia                           147 (28.9%)                                     8 (29.6%)                                   0.938
  Diarrhoea                                       160 (31.5%)                                     8 (29.6%)                                   0.839
  Abdominal pain                                  50 (9.8%)                                       3 (11.1%)                                   0.742
  Radiologic findings -- no./total no. (%)                                                                                                     
  Chest CT                                                                                                                                    0.059
  Single lung                                     90/463 (19.4%)                                  4/26 (15.4%)                                 
  Bilateral lungs                                 354/463 (76.5%)                                 18/26 (69.2%)                                
  Normal                                          19/463 (4.1%)                                   4/26 (15.4%)                                 
  Laboratory findings -- no. (%)                                                                                                              0.807
  SARS‐CoV‐2 in throat swab specimens by RT‐PCR                                                                                                
  Positive                                        325 (64.0%)                                     18 (66.7%)                                   
  Probable positive                               27 (5.3%)                                       2 (7.4%)                                     
  Negative                                        156 (30.7%)                                     7 (25.9%)                                    

Data are presented as median (IQR) or number (percentage). *P* values are calculated from Kruskal--Wallis test, chi‐square test or Fisher's exact test.
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The clinical symptoms of the patients in two groups were similar, but the percentages of involvement were various. The most common symptoms were fever (66.7% and 60.8% in patients with or without conjunctival congestion, respectively), cough (74.1% and 64.8%, respectively) and fatigue (51.9% and 38.6%, respectively). Besides, 40.7% of patients with conjunctival congestion and 42.5% of patients without conjunctival congestion had a temperature over 38.1° C. Of the patients with conjunctival congestion, 29.6% suffered from diarrhoea and 25.9% developed dyspnoea while hospitalized; of the patients without conjunctival congestion, these percentages were 31.5% and 22.2%, respectively. With regard to radiologic findings of the lung, most patients had bilateral involvement (69.2% and 76.5% in patients with or without conjunctival congestion, respectively). All patients underwent SARS‐CoV‐2 detection via nasopharyngeal swabs several times. Respectively, 66.7% and 64.0% of patients were confirmed with positive SARS‐CoV‐2 detection in nasopharyngeal swabs.

Ocular characteristics of COVID‐19 patients by conjunctival congestion {#aos14472-sec-0014}
----------------------------------------------------------------------

The ocular characteristics, including ocular symptoms, recent use of eye drop medication, eye protections and previous eye diseases, are presented in Table [3](#aos14472-tbl-0003){ref-type="table"}.

###### 

Ocular characteristics of COVID‐19 patients by conjunctival congestion.

  **Ocular characteristics**                                 **Without conjunctival congestion (*N* = 508)**   **With conjunctival congestion (*N* = 27)**   **p value**
  ---------------------------------------------------------- ------------------------------------------------- --------------------------------------------- -------------------------------------------------
  Duration of conjunctival congestion -- days                ‐                                                 5.9 ± 4.5                                      
  Ocular symptoms -- no. (%)                                                                                                                                 
  Conjunctival secretion                                     44 (8.7%)                                         8 (29.6%)                                     \<0.001[\*](#aos14472-note-0007){ref-type="fn"}
  Ocular pain                                                18 (3.5%)                                         5 (18.5%)                                     \<0.001[\*](#aos14472-note-0007){ref-type="fn"}
  Foreign body sensation                                     58 (11.4%)                                        5 (18.5%)                                     0.265
  Photophobia                                                13 (2.6%)                                         3 (11.1%)                                     0.041[\*](#aos14472-note-0007){ref-type="fn"}
  Blurred vision                                             65 (12.8%)                                        3 (11.1%)                                     1.000
  Dry eye                                                    102 (20.1%)                                       10 (37.0%)                                    0.035[\*](#aos14472-note-0007){ref-type="fn"}
  Tearing                                                    49 (9.6%)                                         6 (22.2%)                                     0.036[\*](#aos14472-note-0007){ref-type="fn"}
  Itching                                                    49 (9.6%)                                         4 (14.8%)                                     0.329
  Eye drops medication within past 14 days -- no. (%)                                                                                                        
  Ofloxacin                                                  16 (3.1%)                                         5 (18.5%)                                     \<0.001[\*](#aos14472-note-0007){ref-type="fn"}
  Tobramycin                                                 2 (0.4%)                                          2 (7.4%)                                      0.014[\*](#aos14472-note-0007){ref-type="fn"}
  Ganciclovir                                                2 (0.4%)                                          2 (7.4%)                                      0.014[\*](#aos14472-note-0007){ref-type="fn"}
  Artificial tears                                           11 (2.2%)                                         1 (3.7%)                                      0.466
  Wearing glass or goggle -- no. (%)                         142 (28.0%)                                       9 (33.3%)                                     0.545
  Hand--eye contact -- no. (%)                                                                                                                               0.033[\*](#aos14472-note-0007){ref-type="fn"}
  Never                                                      195 (38.4%)                                       8 (29.6%)                                      
  Seldom                                                     273 (53.7%)                                       13 (48.1%)                                     
  Often                                                      40 (7.9%)                                         6 (22.2%)                                      
  Total time of short‐distance reading in a day -- no. (%)                                                                                                   0.934
  \<2 hr                                                     110 (21.7%)                                       7 (25.9%)                                      
  2--4 hr                                                    91 (17.9%)                                        6 (22.2%)                                      
  4--8 hr                                                    163 (32.1%)                                       7 (25.9%)                                      
  8--12 hr                                                   103 (20.3%)                                       5 (18.5%)                                      
  \>12 hr                                                    41 (8.1%)                                         2 (7.4%)                                       
  Chronic eye diseases -- no. (%)                                                                                                                            
  Conjunctivitis                                             30 (5.9%)                                         3 (11.1%)                                     0.228
  Keratitis                                                  13 (2.6%)                                         1 (3.7%)                                      0.520
  Xerophthalmia                                              22 (4.3%)                                         2 (7.4%)                                      0.345
  Cataract                                                   9 (1.8%)                                          0                                             1.000
  Glaucoma                                                   4 (0.8%)                                          0                                             1.000
  Macular disease                                            1 (0.2%)                                          0                                             1.000
  Diabetic retinopathy                                       5 (1.0%)                                          0                                             1.000
  Other retinal disease                                      3 (0.6%)                                          0                                             1.000
  Optic nerve diseases                                       1 (0.2%)                                          0                                             1.000

Data are presented as median (IQR) or number (percentage). *P* values are calculated from Kruskal--Wallis test, chi‐square test or Fisher's exact test.

p value \< 0.05.
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In our study, the average duration of conjunctival congestion was 5.9 ± 4.5 days (mean \[SD\]). More accompanied ocular symptoms were found in patients with conjunctival congestion, including increased conjunctival secretion, ocular pain, photophobia, dry eye and tearing. In addition, a few patients suffered from dry eye in patients with or without conjunctival congestion (37.0% and 20.1%, respectively). According to the evaluation by ophthalmologists, patients with conjunctival congestion received eye drops of ofloxacin (18.5%), tobramycin (7.4%) and ganciclovir (7.4%). As for ocular protections, a total of 33.3% patients with conjunctival congestion and 28.0% patients without conjunctival congestion wore glasses or goggles. More than half of patients ever touched their eyes with their hands. Furthermore, patients with conjunctival congestion tended to touch their eyes frequently (22.2% vs. 7.9%, *P* = 0.033). During the hospitalization, most patients spent a lot of time on short‐distance reading. 307 (60.6%) and 14 (51.9%) patients in two groups spent more than 4 hours per day on reading. A minority of patients had chronic eye diseases, including conjunctivitis, keratitis and xerophthalmia.

Correlations between ocular protections and conjunctival congestion in COVID‐19 patients by multivariate regression analysis {#aos14472-sec-0015}
----------------------------------------------------------------------------------------------------------------------------

Multivariate regression analysis between ocular protections and conjunctival congestion is performed in Table [4](#aos14472-tbl-0004){ref-type="table"}. Model I adjusted for age, gender and smoking history. Model II adjusted for the former factors, highest temperature and SARS‐CoV‐2 detection.

###### 

Correlations between ocular protections and conjunctival congestion in COVID‐19 patients by multivariate regression analysis.

                                         Unadjusted                                                         Model I                                                            Model II
  -------------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------ ------------------------------------------------------------------
  Wearing glass or goggle                                                                                                                                                      
  No                                     1.00                                                               1.00                                                               1.00
  Yes                                    1.29 (0.57, 2.94) 0.546                                            1.31 (0.52, 3.28) 0.565                                            1.24 (0.49, 3.17) 0.648
  Hand--eye contact                                                                                                                                                            
  Never                                  1.00                                                               1.00                                                               1.00
  Seldom                                 1.16 (0.47, 2.85) 0.745                                            0.99 (0.37, 2.69) 0.989                                            0.92 (0.33, 2.59) 0.871
  Often                                  3.66 (1.20, 11.11) 0.022[\*](#aos14472-note-0009){ref-type="fn"}   3.88 (1.12, 13.39) 0.032[\*](#aos14472-note-0009){ref-type="fn"}   4.01 (1.11, 14.55) 0.035[\*](#aos14472-note-0009){ref-type="fn"}
  Total time of short‐distance reading                                                                                                                                         
  \<2 hr                                 1.00                                                               1.00                                                               1.00
  2--4 hr                                1.04 (0.34, 3.19) 0.951                                            1.29 (0.36, 4.65) 0.696                                            1.29 (0.35, 4.76) 0.698
  4--8 hr                                0.67 (0.23, 1.98) 0.473                                            0.62 (0.17, 2.19) 0.454                                            0.59 (0.16, 2.13) 0.417
  8--12 hr                               0.76 (0.23, 2.48) 0.653                                            0.54 (0.13, 2.30) 0.404                                            0.59 (0.14, 2.58) 0.483
  \>12 hr                                0.77 (0.15, 3.84) 0.747                                            0.54 (0.08, 3.51) 0.519                                            0.46 (0.07, 3.17) 0.434

Data are presented as β (95% CI) p value.

p value \< 0.05. Model I adjust for age, gender, smoking history and occupation. Model II adjust for the former factors, highest temperature and SARS‐CoV‐2 detection.
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On univariate analysis, the frequency of hand--eye contact was associated with conjunctival congestion. After adjusting for other clinical factors in multivariate regression analysis, the frequency of hand--eye contact was still correlated with conjunctival congestion in model II. The regression coefficient was 4.01 (95% CI, 1.11--14.55, p = 0.035). No significant relation was fond between wearing glass or goggle, time of reading and conjunctival congestion.

Ocular profiles and clinical characteristics of patients with conjunctival congestion {#aos14472-sec-0016}
-------------------------------------------------------------------------------------

The ocular symptoms, eye drop medications, eye protections, history of eye disease and clinical characteristics of all 27 patients with conjunctival congestion are summarized in Table [5](#aos14472-tbl-0005){ref-type="table"}. The duration of conjunctival congestion, onset date of clinical symptoms and days after clinical symptoms occurring conjunctival congestion are summarized in Fig. [2](#aos14472-fig-0002){ref-type="fig"}.

###### 

Detailed information about the ocular profiles and clinical characteristics of patients with conjunctival congestion.

  **Case**   **Gender**   **Age (years)**   **Ocular symptoms**         **Other ocular characteristics**   **Clinical characteristics**                                                                              
  ---------- ------------ ----------------- --------------------------- ---------------------------------- ------------------------------ -------- ----- ------- -------------------------- ------ ----------------- ------
  1          Male         18                CC, OP, P                   No                                 Yes                            Seldom   Yes   \>12h   No                         36.5   Single lung       \+
  2          Male         44                CC, DE, I, T                No                                 No                             Seldom   No    8‐12h   No                         39.0   Single lung       --
  3          Male         25                CC, BV, DE                  No                                 No                             Often    No    \>12h   No                         36.7   Normal            \+
  4          Female       30                CC, CS, FBS, P, BV, DE, T   No                                 No                             Seldom   No    4‐8h    No                         37.7   Bilateral lungs   +/--
  5          Female       47                CC                          No                                 Yes                            Seldom   Yes   4‐8h    No                         38.5   Bilateral lungs   --
  6          Female       33                CC, CS, DE, T               Tobramycin                         Yes                            Seldom   No    4‐8h    Conjunctivitis             37.5   Bilateral lungs   \+
  7          Male         18                CC, OP, FBS, DE             No                                 Yes                            Seldom   Yes   8‐12h   Conjunctivitis             36.6   Unclear           --
  8          Male         18                CC, CS                      No                                 Yes                            Often    No    8‐12h   No                         36.8   Normal            \+
  9          Male         44                CC, DE                      Ofloxacin                          No                             Seldom   No    4‐8h    Xerophthalmia              36.5   Bilateral lungs   \+
  10         Female       27                CC, OP                      Artificial tears                   Yes                            Often    No    4‐8h    Xerophthalmia              37.8   Normal            \+
  11         Female       28                CC, T                       Ganciclovir                        Yes                            Seldom   No    2‐4h    No                         38.2   Bilateral lungs   \+
  12         Female       64                CC, CS, BV, DE              No                                 No                             Often    Yes   2‐4h    No                         37.5   Bilateral lungs   --
  13         Male         56                CC, CS                      No                                 No                             Never    ‐     \<2h    No                         39.0   Bilateral lungs   \+
  14         Female       61                CC,DC, DE                   No                                 No                             Never    ‐     \<2h    No                         38.5   Single lung       --
  15         Male         42                CC                          No                                 No                             Often    Yes   2‐4h    No                         38.6   Bilateral lungs   \+
  16         Female       40                CC, T                       No                                 No                             Never    ‐     2‐4h    No                         37.7   Bilateral lungs   --
  17         Male         65                CC, FBS                     No                                 No                             Never    ‐     4‐8h    No                         39.0   Bilateral lungs   \+
  18         Male         45                CC                          No                                 Yes                            Seldom   No    \<2h    No                         39.4   Bilateral lungs   \+
  19         Male         62                CC, CS, DE                  Ofloxacin                          No                             Seldom   Yes   \<2h    No                         36.8   Bilateral lungs   --
  20         Female       58                CC                          Ofloxacin Ganciclovir              No                             Never    ‐     \<2h    No                         39.0   Single lung       \+
  21         Female       43                CC, OP, FBS                 No                                 No                             Never    ‐     \<2h    No                         37.0   Bilateral lungs   +/--
  22         Male         65                CC, I                       No                                 Yes                            Seldom   No    8‐12h   No                         37.5   Bilateral lungs   \+
  23         Male         50                CC, I                       Ofloxacin                          No                             Seldom   No    2‐4h    No                         39.0   Bilateral lungs   \+
  24         Female       51                CC, I                       No                                 No                             Seldom   No    2‐4h    No                         38.5   Bilateral lungs   \+
  25         Male         28                CC                          No                                 No                             Never    ‐     4‐8h    No                         37.5   Bilateral lungs   \+
  26         Male         29                CC, CS, FBS, DE, I          Ofloxacin Tobramycin               No                             Often    No    8‐12h   Conjunctivitis Keratitis   36.5   Normal            \+
  27         Female       51                CC, OP, P                   No                                 No                             Never    ‐     \<2h    No                         36.5   Bilateral lungs   \+

CC, conjunctival congestion; CS, conjunctival secretion; OP, ocular pain; FBS, foreign body sensation; P, photophobia; BV, blurred vision; DE, dry eye; T, tearing; and I, itching.

+, positive; +/--, probable positive; and --, negative.
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![Detailed information about the duration of conjunctival congestion, the onset date of clinical symptoms in 27 patients with conjunctival congestion. (A) The numbers in boxes are calendar dates from 20 January 2019 to 7 March 2020. Dark grey box -- onset date of the first clinical symptoms; light grey box -- conjunctival congestion. (B) Days after clinical symptoms occurring conjunctival congestion. Four (14.8%) patients had conjunctival congestion as an initial symptom.](AOS-9999-na-g002){#aos14472-fig-0002}

Eight patients had conjunctival congestion and increased conjunctival secretion (cases 4, 6, 8, 12, 13, 14, 19 and 26). Five patients had tearing (cases 2, 4, 6, 11 and 16). Five patients also had ocular pain (cases 1, 7, 10, 21 and 27), and five patients had foreign body sensation in the eyes (cases 4, 7, 17, 21 and 26). Nineteen patients ever touched their eyes with their hands, and 13 (cases 2, 3, 4, 6, 8, 9, 10, 11, 18, 22, 23, 24 and 26) of them did not wash their hands before touching their eyes. Of the patients with conjunctival congestion, most had bilateral lung involvement indicated by chest CT (18/26, 69.2%) and positive PCR results in SARS‐CoV‐2 detection (18, 66.7%).

The duration of conjunctival congestion ranged from 2 to 24 days. Conjunctival congestion appeared mostly after the first clinical symptoms of COVID‐19. Four patients (cases 14, 17, 21 and 25) had conjunctival congestion as an initial symptom. Seven patients (cases 5, 7, 11, 16, 18, 22 and 23) developed conjunctival congestion within three days after the beginning of clinical symptoms.

Discussion {#aos14472-sec-0017}
==========

To date, the epidemiologic data on the incidence of conjunctivitis in COVID‐19 patients range from 0.8% to 7.9% (Guan et al., [2020](#aos14472-bib-0005){ref-type="ref"}; Wu et al. [2020](#aos14472-bib-0015){ref-type="ref"}; Xia et al., [2020](#aos14472-bib-0016){ref-type="ref"}; Zhang et al., [2020](#aos14472-bib-0013){ref-type="ref"}) However, the precise incidence of ocular manifestations relative to COVID‐19 is unclear. In our present study, we found that (1) of a total of 535 COVID‐19 patients identified, 27 patients (5.0%) presented with conjunctival congestion; (2) the accompanied ocular symptoms were different between the two groups with or without conjunctival congestion, and dry eye (37.0%), conjunctival secretion (29.6%), tearing (22.2%), ocular pain (18.5%) ranked in the top four in patients with conjunctival congestion group; and 3) simultaneously, we also found the occurrence of conjunctival congestion in COVID‐19 patients correlated with a higher frequency of hand--eye contact (22.2% vs. 7.9%).

Most recently, Wu et al. ([2020](#aos14472-bib-0015){ref-type="ref"}) found that one‐third of patients with COVID‐19 had ocular abnormalities, consistent with conjunctivitis, including conjunctival hyperaemia or increased secretions. However, these epidemiological investigations did not fully observe other ocular manifestations besides conjunctival congestion. The present epidemiologic study summarized more manifestations present on the ocular surface mainly in the mild cases. We enrolled 535 patients and similarly found that COVID‐19 patients exhibit ocular manifestations including conjunctival congestion (27), secretion (52), foreign body sensation (63), blurred vision (68), dry eye (112), itching (53), photophobia (16) and tearing (55). The demographics and baseline characteristics of COVID‐19 patients with or without conjunctival congestion have no significant difference. The incidence of conjunctival congestion in our study is 5.0%, which is lower than Wu's report (3/38, 7.9%) (Wu et al. [2020](#aos14472-bib-0015){ref-type="ref"}) but higher than that in Zhong's large sample report (9/1099, 0.8%) (Guan et al., [2020](#aos14472-bib-0005){ref-type="ref"}) and Xia's study (1/30, 3.3%) (Xia et al., [2020](#aos14472-bib-0016){ref-type="ref"}). Wu found that conjunctival congestion occurred in patients with more severe COVID‐19. Zhong and colleagues extracted data from 552 hospitals in 30 provinces, autonomous regions and municipalities in China, while 21 common‐type and nine severe‐type COVID‐19 patients were observed by Xia in Zhejiang Province. However, the COVID‐19 patients in our study mainly came from Tongji Hospital (271) or Mobile Cabin Hospital (264) in Wuhan, and they were mostly common‐type. Therefore, the clinical type and region may be the causes of the various incidence of conjunctival congestion in COVID‐19 patients.

Given that SARS‐CoV‐2 nucleic acid was not detected in patients' conjunctival swab sample, we did not diagnosis them with conjunctivitis directly. However, these 27 patients did not report any other chronic eye diseases nor any symptoms associated with intraocular diseases (such as iritis, choroiditis and retinal disease), which suggests that the possibility of endophthalmitis is very small, and conjunctivitis may be the primary cause of the conjunctival congestion. Moreover, conjunctival congestion and positive RT‐PCR in pharyngeal swabs were found at the same time in four COVID‐19 patients (cases 11, 20, 23 and 24) who reported no chronic eye diseases. Our previous study found a rare case of nosocomial SARS‐CoV‐2 infection initiated with conjunctivitis in a nurse, and both the conjunctival and nasopharyngeal swabs tested for SARS‐CoV‐2 were positive.(Sun et al., [2020](#aos14472-bib-0013){ref-type="ref"}) However, the aim of this epidemiological study is to investigate the ocular manifestations of COVID‐19 patients, and most of them were no longer exhibit conjunctival congestion when they performed investigation, which contribute to the conjunctival swab test data missing. Our study also found that the average duration of conjunctival congestion was 5.9 ± 4.5 days (mean \[SD\]), ranging from two to twenty‐four days. Four patients diagnosed with COVID‐19 patients had an initial symptom of conjunctival congestion, which reminds us that ocular manifestations occur early in the course of COVID‐19. Therefore, healthcare workers should pay attention to patients' ocular symptoms and manifestations in the early stage of disease and should perform a conjunctival swab test for SARS‐CoV‐2 in patients with conjunctival congestion.

SARS‐CoV‐2 is thought to be transmitted from person to person mainly through respiratory droplets or close contact (Xu et al. [2020](#aos14472-bib-0017){ref-type="ref"}). The ocular surface is exposed to the outside environment, which may become a potential gateway for pathogens such as viruses to invade the human body.(Belser et al. [2013](#aos14472-bib-0002){ref-type="ref"}; Stiles [2014](#aos14472-bib-0011){ref-type="ref"}) Moreover, eye rubbing is another high risk factor for virus transmission, which has been confirmed in adenovirus‐induced conjunctivitis.(Artieda et al. [2010](#aos14472-bib-0001){ref-type="ref"}) Simultaneously, we found that a total of 332 COVID‐19 patients had a history of hand--eye contact, including 286 cases who reported seldom hand--eye contact and 46 who reported frequent hand--eye contact. Among the 27 cases with conjunctival congestion, 19 (70.4%) had a history of hand--eye contact, 6 (22.2%) with frequent contact. The results of multivariate regression analysis also showed that the high‐frequency hand--eye contact correlated with conjunctival congestion, suggesting that hand--eye contact is possibly a risk factor for conjunctival congestion in COVID‐19 patients.

The present study also found that the incidence of dry eye, blurred vision and foreign body sensation was the top three ocular symptoms in all patients (20.9%, 12.7% and 11.8%), which could be due to the fact that COVID‐19 patients are more likely to have a lot of time to use electronic products. Our results showed that 321 of 535 COVID‐19 patients spent more than four hours per day on short‐distance reading and 43 of them even spent exceeded 12 hours per day on reading. Because of this, healthcare workers should propose patients reading scientifically and reducing short‐distance reading time.

Consistent with previous studies, SARS‐CoV‐2‐infected patients developed respiratory disorders with initial symptoms of fever, cough, chest stuffiness and fatigue, which quickly progress to pneumonia and even shortness of breath (Chen et al. [2020](#aos14472-bib-0003){ref-type="ref"}, [2020](#aos14472-bib-0004){ref-type="ref"}a,b; Huang et al. [2020](#aos14472-bib-0006){ref-type="ref"}; Zhu et al. [2020](#aos14472-bib-0020){ref-type="ref"}). However, extra‐pulmonary manifestations were also observed in a number of patients at the onset of the illness, including headache, myalgia or arthralgia, and diarrhoea, and some even presented with asymptomatic infection (Chen et al. [2020](#aos14472-bib-0003){ref-type="ref"}, [2020](#aos14472-bib-0004){ref-type="ref"}a,b; Rothe et al. [2020](#aos14472-bib-0010){ref-type="ref"}). We also found that most of the enrolled COVID‐19 patients had bilateral lung accumulation (372/489), and the SARS‐CoV‐2 RT‐PCR test was positive at least once in 343 patients. However, no significant difference was observed between the COVID‐19 patients with or without conjunctival congestion.

The present study has some limitations. First, the sample size was relatively small and the covered population excluded severe cases, since only patients with mild symptoms could complete our electronic questionnaire or telephone follow‐up. Second, most of the ocular manifestations were self‐reported retrospectively by the questionnaire owing to a physical examination by slit lam is not feasible, and conjunctival swab test for SARS‐CoV‐2 was not performed in early stage. However, a representative picture of conjunctival congestion was send to patients for reference, which made the conjunctival congestion data reasonable. To date, this is the most comprehensive survey with the largest sample related to the eyes. Fourth, no normal population was observed in our study; therefore, a normal control group should be included for comparison in future studies.

Conclusions {#aos14472-sec-0018}
===========

In conclusion, the significance of understanding the ocular manifestations of our present study lies in (1) helping to deepen the understanding of COVID‐19‐related eye diseases; identify ocular symptoms, manifestations and clinical outcomes; and enrich the symptom spectrum of COVID‐19; (2) observing the difference between the COVID‐19 patients with or without conjunctival congestion; and (3) providing a clue that hand--eye contact correlated with conjunctival congestion in COVID‐19 patients. Our findings may provide useful information for the diagnosis and treatment of COVID‐19. Simultaneously, it also provides clues for patients with ocular symptoms and manifestations in the early stage of disease should perform a conjunctival swab test for SARS‐CoV‐2 in patients with conjunctival congestion.
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